DNA filter elution methods in anticancer drug development

  • Kurt W. Kohn
Part of the Cancer Treatment and Research book series (CTAR, volume 36)


DNA filter elution methods are widely used to assess DNA lesions such as single- and double-strand breaks, alkali-labile sites, interstrand crosslinks, and DNA-protein crosslinks in mammalian cells [1]. Such DNA lesions are likely to be involved in the production of cytotoxic and mutagenic effects of drugs and chemicals, and the assays are often sensitive enough to detect actions at doses pertinent to the mechanisms of antitumor and carcinogenic effects. Recent work has utilized the technique to investigate the factors that determine the sensitivities of different cell types to anti-cancer drugs. This chapter reviews some recent results, mainly from my laboratory, that illustrate how the technique can be applied to studies of drug action mechanisms. Before going on to these findings, however, current knowledge of how the technique works will be summarized.


Strand Break L1210 Cell Interstrand Crosslinking Alkaline Elution Filter Elution 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Kohn KW, Ewig RA, Erickson LC, and Zwelling LA: Measurement of strand breaks and crosslinks in DNA by alkaline elution. In: DNA Repair: A Laboratory Manual of Research Techniques Friedberg EC and Hanawalt PC (eds). New York: Marcel Dekker, pp 379–401, 1981.Google Scholar
  2. 2.
    Kohn KW: DNA as a target in cancer chemothrapy: Measurement of macromolecular DNA damage produced in mammalian cells by anticancer agents and carcinogens. Methods Cancer Res 16:291–345, 1979.Google Scholar
  3. 3.
    Kohn KW, Friedman CA, Ewig RA, and Iqbal ZM: DNA chain growth during replication of asynchronous L1210 cells. Alkaline elution of large DNA segments from cells lysed on filters. Biochemistry 13:4134–4139, 1974.PubMedCrossRefGoogle Scholar
  4. 4.
    Kohn KW, Erickson LC, Ewig RA, and Friedman CA: Fractionation of DNA from mammalian cells by alkaline elution. Biochemistry 15:4629–4637, 1976.PubMedCrossRefGoogle Scholar
  5. 5.
    Nicolini C, Belmont A, Zietz S, Maura A, Pino A, Robbiano L, and Brambilla G: Physico-chemical model for DNA alkaline elution: New experimental evidence and differential role of DNA length, chain fexibility, and superpacking. J Theor Biol 100:341–357, 1983.PubMedCrossRefGoogle Scholar
  6. 6.
    Bradley MO and Kohn KW: X-ray induced DNA double-strand break production and repair in mammalian cells as measured by neutral filter elution. Nucleic Acids Res 7:793–804, 1979.PubMedCrossRefGoogle Scholar
  7. 7.
    D’lncalci M, Covey JM, Zaharko DS, and Kohn KW: DNA alkali-labile sites induced by incorporation of 5-Aza-2’-deoxycytidine into DNA of mouse leukemia L1210 cells. Cancer Res 45:3197–3202, 1985.Google Scholar
  8. 8.
    D’lncalci M, Szmigiero L, Erickson LC, Hartley JA, and Kohn KW: A filter incubation method for the determination of potentially crosslinked sites in DNA in mammalian cells. Anal Biochem 150:161–165, 1985.CrossRefGoogle Scholar
  9. 9.
    Nicolini C, Robbiano L, Pino A, Maura A, Finolio R, and Brambilla G: Higher sensitivity for the detection of chemically-induced DNA damage: Role of DNA unfolding in determining alkaline elution rate. Carcinogenesis 6:385–389, 1985.PubMedCrossRefGoogle Scholar
  10. 10.
    Ewig RA and Kohn KW: DNA-protein crosslinking and DNA interstrand crosslinking by haloethylnitrosoureas in L1210 cells. Cancer Res 38:1762–1768, 1978.PubMedGoogle Scholar
  11. 11.
    Kohn KW and Ewig RA: DNA-protein crosslinking by transplatinum(II) diammminedich-loride in mammalian cells, a new method of analysis. Biochim Biophys Acta 562:32–40, 1979.PubMedGoogle Scholar
  12. 12.
    Ewig RA and Kohn KW: DNA damage and repair in mouse leukemia L1210 cells treated with nitrogen mustard, 1,3-bis (2-chloroethyl)-l-nitrosourea, and other nitrosoureas. Cancer Res 37:2114–2122, 1977.PubMedGoogle Scholar
  13. 13.
    Lown JW and Chauhan SM: Mechanism of action of (2-haloethyl) nitrosoureas on DNA. Isolation and reactions of postulated 2-(alkylimino)-3-nitrosooxzolidine intermediates in the decomposition of 1,3-cyclohexyl-, and l-(2-chloroethyl)-3-(4’-trans-methylcyclohexyl)-l-nitrosourea. J Med Chem 24:270–279, 1981.PubMedCrossRefGoogle Scholar
  14. 14.
    Tong WP, Kirk MC, Ludlum DB: Formation of the crosslink l-[N(3)-deoxycytidyl], 2[-N (l)-deoxyguanosinyl]ethane in DNA treated with N, N’-bis(2-chloroethyl)-N-nitrosourea. Cancer Res 42:3102–3105, 1982.PubMedGoogle Scholar
  15. 15.
    Kohn KW: Interstrand crosslinking of DNA by l,3-bis(2-chloroethyl)-l-nitrosourea and other l-(2-haloethyl)-l-nitrosoureas. Cancer Res 37:1450–1454, 1977.PubMedGoogle Scholar
  16. 16.
    Lown JW, McLaughlin LW, and Chang YM: Mechanism of action of 2-haloethylnitrosoureas on DNA and its relation to their antileukemic properties. Bioorg Chem 7:97–110, 1978.CrossRefGoogle Scholar
  17. 17.
    Day RS, Ziolkowski CH, Scudiero DA, Meyer SA, Lubiniecki AS, Girardi AJ, Galloway SM, and Bynum GD: Defective repair of alkylated DNA by human tumor and SV 40-transformed human cell strains. Nature 288:724–727, 1980.PubMedCrossRefGoogle Scholar
  18. 18.
    Day RS, Ziolkowski CH, Scudiero DA, Meyer SA, and Mattern MR: Human tumor cell strains defective in the repair of alkylation damage. Carcinogenesis 1:21–32, 1980.CrossRefGoogle Scholar
  19. 19.
    Erickson LC, Laurent G, Sharkey NA, and Kohn KW: DNA cross-linking and monoad-duct repair in nitrosourea-treated human tumour cells. Nature 288:727–729, 1980.PubMedCrossRefGoogle Scholar
  20. 20.
    Brent TP: Suppression of cross-link formation in chloroethyl-nitrosourea-treated DNA by an activity in extracts of human leukemic lymphoblasts. Cancer Res 44:1887–1892, 1984.PubMedGoogle Scholar
  21. 21.
    Robins P, Harris AL, Goldsmith I, and Lindahl T: Crosslinking of DNA induced by chloroethylnitrosourea is prevented by 06-methylguanine-DNA methyltransferase. Nucleic Acids Res 11:7743–7758, 1983.PubMedCrossRefGoogle Scholar
  22. 22.
    Tong WP, Kirk MC, and Ludlum DB: Mechanism of action of the nitrosoureas — V. Formation of 06-(2-fluoroethyl)guanine and its possible role in the crosslinking of deoxyribonucleic acid. Biochem Pharmacol 32:2011–2015, 1983.PubMedCrossRefGoogle Scholar
  23. 23.
    Tong WP, Kohn KW, and Ludlum DB: Modifications of DNA by different haloethylnitro-soureas. Cancer Res 42:4460–4464, 1982.PubMedGoogle Scholar
  24. 24.
    Kann HE, Kohn KW, and Lyles JM: Inhibition of DNA repair by the l,3-bis(2-chloroethyl)-l-nitrosourea breakdown product, 2-chloroethyl isocyanate. Cancer Res 34:398–402, 1974.PubMedGoogle Scholar
  25. 25.
    Kann HE, Kohn KW, Widerlite L, and Gullion D: Effects of l,3-bis(2-chloroethyl)-l-nitrosourea and related compounds on nuclear RNA metabolism. Cancer Res 34:1982–1988, 1974.PubMedGoogle Scholar
  26. 26.
    Kann HE: Comparison of biochemical and biological effects of four nitrosoureas with differing carbamoylating activities. Cancer Res 38:2363–2366, 1978.PubMedGoogle Scholar
  27. 27.
    Kann HE, Schott MA, and Petkas A: Effects of structure and chemical activity on the ability of nitrosoureas to inhibit DNA repair. Cancer Res 40:50–55, 1980.PubMedGoogle Scholar
  28. 28.
    Erickson LC, Bradley MO, and Kohn KW: Differential inhibition of the rejoining of x-ray-induced DNA strand breaks in normal and transformed human fibroblasts treated with l,3-bis(2-chloroethyl)-l-nitrosourea in vitro. Cancer Res 38:803–808, 1978.Google Scholar
  29. 29.
    Fornace AJ, Kohn KW, and Kann HE: Inhibition of the ligase step of excision repair by 2-chloroethylisocyanate, a decomposition product of l,3-bis(2-chloroethyl)-nitrosourea. Cancer Res 38:1064–1069, 1978.PubMedGoogle Scholar
  30. 30.
    Erickson LC, Bradley MO, and Kohn KW: Strand breaks in DNA from normal and transformed human cells treated with l,3-bis(2-chloroethyl)-l-nitrosourea. Cancer Res 37:3744–3750, 1977.PubMedGoogle Scholar
  31. 31.
    Yarosh DB, Foote RS, Mitra S, Day RS: Repair of 0(6)-methylguanine in DNA by demethylation is lacking in Mer“ human tumor cell strains. Carcinogenesis 4:199–205, 1983.PubMedCrossRefGoogle Scholar
  32. 32.
    Yarosh DB, Rice M, Day RS, Foote RS, and Mitra S: 06-methylguanine-DNA methyl-transferase in human cells. Mutat Res 13:27–36, 1984.Google Scholar
  33. 33.
    Brent TP, Houghton PJ, and Houghton JA: 06-alkylguanine-DNA alkyltransferase activity correlates with the therapeutic response of human rhabdomyosarcoma xenografts to l-(2-chloroethyl)-3-(trans-4-methylcyclohexyl)-l-nitrosourea. Proc Natl Acad Sci USA 82:2985–2989, 1985.PubMedCrossRefGoogle Scholar
  34. 34.
    Zlotogorski C and Erickson LC: Pretreatment of normal human fibroblasts and human colon carcinoma cells with MMNG allows chloroethyl-nitrosourea to produce DNA inter-strand crosslinks not observed in cells treated with chloroethylnitrosourea alone. Carcinogenesis 4:759–763, 1983.PubMedCrossRefGoogle Scholar
  35. 35.
    Zlotogorski C and Erickson LC: Pretreatment of human colon cells with DNA methylating agents inhibits their ability to repair chloroethyl monadducts. Carcinogenesis 5:83–87, 1984.PubMedCrossRefGoogle Scholar
  36. 36.
    Gibson NW, Zlotogorski C, and Erickson LC: Specific DNA repair mechanisms may protect some human tumor cells from DNA interstrand crosslinking by chloroethylnitro-soureas but not from crosslinking by other anti-tumor alkylating agents. Carcinogenesis 6:445–450, 1985.PubMedCrossRefGoogle Scholar
  37. 37.
    Sariban E, Erickson LC, and Kohn KW: Effects of carbamoylation on cell survival and DNA repair in normal human embryo cells (IMR-90) treated with various l-(2-chloroethyl)-l-nitrosoureas. Cancer Res 44:1352–1357, 1984.PubMedGoogle Scholar
  38. 38.
    Shealy YF, Krauth CA, Struck RF, and Montgomery JA: 2-haloethylating agents for cancer chemotherapy. 2-haloethylsulfonates. J Med Chem 26:1168–1173, 1983.PubMedCrossRefGoogle Scholar
  39. 39.
    Shealy YF, Krauth CA, Laster WR, Jr: 2-chloroethyl(methylsulfonyl)methanesulfonate and related (methylsulfonyl)methanesulfonates. Antineoplastic activity in vivo. J Med Chem 664–670, 1984.CrossRefGoogle Scholar
  40. 40.
    Gibson NW, Rickson LC, and Kohn KW: DNA damage and differential cytotoxicity produced in human cells by 2-chloroethyl(methylsulfonyl)methanesulfonate (NSC 338947), a new DNA-chloroethylating agent. Cancer Res 45:1674–1679, 1985.PubMedGoogle Scholar
  41. 41.
    Driscoll JS, Dudeck L, Congleton G, and Geran RI: Potential CNS antitumor agents VI: Aziridinylbenzoquinones III. J Pharm Sci 68:185–188, 1979.PubMedCrossRefGoogle Scholar
  42. 42.
    Curt GA, Kelley JA, Kuftan CV, Smith BH, Kornblith PL, Young RC, and Collins JM: Phase II and pharmacokinetic study of aziridinylbenzoquinone [2,5-diaziridinyl-3,6-bis (carboethoxamino)-l,4-benzoquinone, diaziquone, NSC 182986] in high-grade gliomas. Cancer Res 43:6102–6105, 1983.PubMedGoogle Scholar
  43. 43.
    Case DC and Hayes DM: Aziridinylbenzoquinone (AZQ) (NSC 182986): Phase II study in lymphoma. Proc Am Assoc Cancer Res 24:471, 1983.Google Scholar
  44. 44.
    Szmigiero L, Erickson LC, Ewig RA, and Kohn KW: DNA strand scission and crosslinking by diaziridinylbenzoquinone (diaziquone) in human cells and relation to cell killing. Cancer Res 44:4447–4452, 1984.PubMedGoogle Scholar
  45. 45.
    Szmigiero L and Kohn KW: Mechanisms of DNA strand breakage and interstrand cross-linking by diaziridinylbenzoquinone (diaziquone) in isolated nuclei from human cells. Cancer Res 44:4453–4457, 1984.PubMedGoogle Scholar
  46. 46.
    King CL, Hittelman WN, and Loo TL: Induction of DNA strand breaks and crosslinks by 2,5-diaziridinyl-3,6-bis(carboethoxamino)-l,4-bezoquinone in Chinese hamster ovary cells. Cancer Res 44:5634–5637, 1984.PubMedGoogle Scholar
  47. 47.
    King CL, Wong SK, and Loo TL: Alkylation of DNA by the new anticancer agent 3,6-diaziridinyl-2,5-bis(carboethoxamino)-l,4-benzoquinone (AZQ). Eur J Cancer Clin Oncol 20:261–264, 1984.PubMedCrossRefGoogle Scholar
  48. 48.
    Pascoe JM and Roberts JJ: Interactions between mammalian cell DNA and inorganic platinum compounds-II. Interstrand crosslinking of isolated and cellular DNA by platinum (IV) compounds. Biochem Pharmacol 23:1359–1365, 1974.PubMedCrossRefGoogle Scholar
  49. 49.
    Harder H: Renaturation effects of cis and trans platinum II and IV compounds on calf thymus DNA. Chem Biol Interact 10:27–39, 1975.PubMedCrossRefGoogle Scholar
  50. 50.
    Zwelling LA, Kohn KW, Ross WE, Ewig RA, Anderson T: Kinetics of formation and disappearance of DNA crosslinking effect in mouse leukemia L1210 cells treated with cis-and trans-diamminedichloroplatinum(II). Cancer Res 38:1762–1768, 1978.PubMedGoogle Scholar
  51. 51.
    Filipski J, Kohn KW, and Bonner WM: The nature of inactivating lesions produced by platinum(II) complexes in phage lambda DNA. Chem Biol Interact 32:321–330, 1980.PubMedCrossRefGoogle Scholar
  52. 52.
    Laurent G, Erickson LC, Sharkey NA, and Kohn KW: DNA crosslinking and cytotoxicity induced by cis-diamminedichloroplatinum(II) in human normal and tumor cell lines. Cancer Res 41:3347–3351, 1981.PubMedGoogle Scholar
  53. 53.
    Ducore JM, Erickson LC, Zwelling LA, Laurent G, and Kohn KW: Comparative studies of DNA cross-linking and cytotoxicity in Burkitt’s lymphoma cell lines treated with cis-diamminedichloroplatinum(II) and L-phenylalanine mustard. Cancer Res 42:897–902, 1982.PubMedGoogle Scholar
  54. 54.
    Plooy, ACM, van Dijk M, Berends F, and Lohman PHM: Formation and repair of DNA interstrand crosslinks in relation to cytotoxicity and unscheduled DNA synthesis induced in control and mutant human cells treated with ds-diamminedichloroplatinum(II). Cancer Res 45:4178–4184, 1985.PubMedGoogle Scholar
  55. 55.
    Strandberg MC, Bresnick E, and Eastman A: The significance of DNA crosslinking to cis-diamminedichloroplatinum(II)-induced cytotoxcity in sensitive and resistant lines of murine leukemia L1210 cells. Chem Biol Interact 39:169–180, 1982.PubMedCrossRefGoogle Scholar
  56. 56.
    Meyn RE, Jenkins SF, and Thompson LH: Defective removal of DNA crosslinks in a repair-deficient mutant of Chinese hamster cells. Cancer Res 42:3106–3110, 1982.PubMedGoogle Scholar
  57. 57.
    Micetich K, Zwelling LA, and Kohn KW: Quenching of DNA: Platinum(II) monoadducts as a possible mechanism of resistance to cis-diamminedichloroplatinum(II) in L1210 cells. Cancer Res 43:3609–3613, 1983.PubMedGoogle Scholar
  58. 58.
    Suzukake K, Petro BJ, and Vistica DT: Reduction in glutathione content of L-PAM resistant L1210 cells confers drug sensitivity. Biochem Pharmacol 31:121–124, 1982.PubMedCrossRefGoogle Scholar
  59. 59.
    Suzukake K, Vistica BP, and Vistica DT: Dechlorination of L-phenylalanine mustard by sensitive and resistant tumor cells and its relationship to intracellular glutathione content. Biochem Pharmacol 32:165–167, 1983.PubMedCrossRefGoogle Scholar
  60. 60.
    Ross WE, Glaubiger DL, and Kohn KW: Protein-associated DNA breaks in cells treated with adriamycin or ellipticine. Biochim Biophys Acta 519:23–30, 1978.PubMedGoogle Scholar
  61. 61.
    Fornace AJ, Kohn KW, and Kann HE: DNA single-strand breaks during repair of UV damage in human fibroblasts and abnormalities of repair in Xeroderma pigmentosum. Proc Natl Acad Sci 73:39–43, 1976.PubMedCrossRefGoogle Scholar
  62. 62.
    Ross WE, Glaubiger D, and Kohn KW: Qualitative and quantitative aspects of intercalator-induced DNA strand breaks. Biochim Biophys Acta 562:41–50, 1979.PubMedGoogle Scholar
  63. 63.
    Filipski J, Yin J, and Kohn KW: Reconstitution of intercalator-induced DNA scission by an active component from nuclear extracts. Biochim Biophs Acta 741:116–122, 1983.Google Scholar
  64. 64.
    Chen GL, Yang L, Rowe TC, Halligan BD, Tewey KM, and Liu LF: Nonintercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II. J Biol Chem 259:13560–13566, 1984.PubMedGoogle Scholar
  65. 65.
    Nelson EM, Tewey KM, and Liu F: Mechanism of antitumor drug action: Poisoning of mammalian DNA topoisomerase II on DNA by 4’-(9-acridinylamino)-methanesulfon-m-anisidide. Proc Natl Acad Sci USA 81:1361–1365, 1984.PubMedCrossRefGoogle Scholar
  66. 66.
    Tewey KM, Chen GL, Nelson EM, and Liu LF: Intercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II. J Biol Chem 259:9182–9187, 1984.PubMedGoogle Scholar
  67. 67.
    Minford JK, Pommier Y, Filipski Y, Kohn KW, Kerrigan D, Mattern M, Michaels S, Schwartz R, and Zwelling LA: Isolation of intercalator-dependent protein-linked DNA strand cleavage activity from cell nuclei and identification as topoisomerase II. Biochemistry (25:9–16), 1986.PubMedCrossRefGoogle Scholar
  68. 68.
    Glisson BS, Smallwood SE, and Ross WE: Characterization of VP-16-induced DNA damage in isolated nuclei from L1210 cells. Biochim Biophys Acta 783:74–79, 1984.PubMedGoogle Scholar
  69. 69.
    Ross WE, and Bradley MO: DNA double-strand breaks in mammalian cells after exposure to intercalating agents. Biochim Biophys Acta 654:129–134, 1981.PubMedGoogle Scholar
  70. 70.
    Ross W, Rowe T, Glisson B, Yalowich J, and Liu L: Role of topoisomerase II in mediating epipodophyllotoxin-induced DNA cleavage. Cancer Res 44:5057–5860, 1984.Google Scholar
  71. 71.
    Zwelling LA, Michaels S, Erickson LC, Ungerleider RS, Nichols M, Kohn KW: Protein-associated deoxyribonucleic acid strand breaks in L1210 cells treated with the deoxyribo-nucleic acid intercalating agents 4’-(9-acridinylamino) methanesulfon-M-anisidide and adriamycin. Biochemistry 20:6553–6663, 1981.PubMedCrossRefGoogle Scholar
  72. 72.
    Zwelling LA, Kerrigan D, and Michaels S: Cytotoxicity and DNA strand breaks by 5-iminodaunorubicin in mouse leukemia L1210 cells: Comparison with adriamycin and 4’-(9-acridinylamino)methanesulfon-M-anisidide. Cancer Res 42:2687–2691, 1982.PubMedGoogle Scholar
  73. 73.
    Zwelling LA, Michaels S, Kerrigan D, Pommier Y, and Kohn KW: Protein-associated deoxyribonucleic acid strand breaks produced in mouse leukemia L1210 cells by ellipticine and 2-methyl-9-hydroxyellipticinium. Biochem Pharmacol 31:3261–3267, 1982.PubMedCrossRefGoogle Scholar
  74. 74.
    Pommier Y, Schwartz RE, Kohn KW, and Zwelling LA: Formation and rejoining of deoxyribonucleic acid double-strand breaks induced in isolated cell nuclei by antineoplastic intercalating agents. Biochemistry 23:3194–3201, 1984.PubMedCrossRefGoogle Scholar
  75. 75.
    Pommier Y, Kerrigan D, Schwartz R, and Zwelling LA: The formation and resealing of intercalator-induced DNA strand breaks in isolated L1210 cell nuclei. Biochem Biophys Res Commun 107:576–583, 1982.PubMedCrossRefGoogle Scholar
  76. 76.
    Filipski J and Kohn KW: Ellipticine-induced protein-associated DNA breaks in isolated L1210 nuclei. Biochim Biophys Acta 698:280–286, 1982.PubMedGoogle Scholar
  77. 77.
    Long BH, Musial ST, and Brattain MG: Comparison of cytotoxicity and DNA breakage activity of congeners of podophyllotoxin including VP16213 and VM26: A quantitative structure-activity relationship. Biochemistry 23:1183–1188, 1984.PubMedCrossRefGoogle Scholar
  78. 78.
    Long BH, Musial ST, and Brattain MG: Single- and double-strand breakage and repair in human lung adenocarcinoma cells exposed to etoposide and teniposide. Cancer Res 45:3106–3112, 1985.PubMedGoogle Scholar
  79. 79.
    Waring MJ: DNA-binding characteristics of acridinylmethane-sulphonanilide drugs: Comparison with antitumor properties. Eur J Cancer 12:995–1001, 1976.PubMedGoogle Scholar
  80. 80.
    Pommier Y, Schwartz RE, Zwelling LA, Kerrigan D, Mattern, MR, Charcosset JY, Jacquemin-Sablon A, and Kohn KW: Reduced formation of protein-associated DNA strand-breaks in Chinese hamster cells resistant to topoisomerase II inhibitors. Cancer Res 46:611–616, 1986.PubMedGoogle Scholar

Copyright information

© Martinus Nijhoff Publishers, Boston 1987

Authors and Affiliations

  • Kurt W. Kohn

There are no affiliations available

Personalised recommendations